160 related articles for article (PubMed ID: 11773078)
1. Kinetic analysis of the interaction between vitronectin and the urokinase receptor.
Okumura Y; Kamikubo Y; Curriden SA; Wang J; Kiwada T; Futaki S; Kitagawa K; Loskutoff DJ
J Biol Chem; 2002 Mar; 277(11):9395-404. PubMed ID: 11773078
[TBL] [Abstract][Full Text] [Related]
2. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?
Deng G; Curriden SA; Wang S; Rosenberg S; Loskutoff DJ
J Cell Biol; 1996 Sep; 134(6):1563-71. PubMed ID: 8830783
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin.
Deng G; Curriden SA; Hu G; Czekay RP; Loskutoff DJ
J Cell Physiol; 2001 Oct; 189(1):23-33. PubMed ID: 11573201
[TBL] [Abstract][Full Text] [Related]
4. The uPA receptor and the somatomedin B region of vitronectin direct the localization of uPA to focal adhesions in microvessel endothelial cells.
Salasznyk RM; Zappala M; Zheng M; Yu L; Wilkins-Port C; McKeown-Longo PJ
Matrix Biol; 2007 Jun; 26(5):359-70. PubMed ID: 17344041
[TBL] [Abstract][Full Text] [Related]
5. A method for defining binding sites involved in protein-protein interactions: analysis of the binding of plasminogen activator inhibitor 1 to the somatomedin domain of vitronectin.
Royle G; Deng G; Seiffert D; Loskutoff DJ
Anal Biochem; 2001 Sep; 296(2):245-53. PubMed ID: 11554720
[TBL] [Abstract][Full Text] [Related]
6. Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region.
Gårdsvoll H; Ploug M
J Biol Chem; 2007 May; 282(18):13561-72. PubMed ID: 17355965
[TBL] [Abstract][Full Text] [Related]
7. Stabilizing a flexible interdomain hinge region harboring the SMB binding site drives uPAR into its closed conformation.
Zhao B; Gandhi S; Yuan C; Luo Z; Li R; Gårdsvoll H; de Lorenzi V; Sidenius N; Huang M; Ploug M
J Mol Biol; 2015 Mar; 427(6 Pt B):1389-1403. PubMed ID: 25659907
[TBL] [Abstract][Full Text] [Related]
8. Different mechanisms define the antiadhesive function of high molecular weight kininogen in integrin- and urokinase receptor-dependent interactions.
Chavakis T; Kanse SM; Lupu F; Hammes HP; Müller-Esterl W; Pixley RA; Colman RW; Preissner KT
Blood; 2000 Jul; 96(2):514-22. PubMed ID: 10887113
[TBL] [Abstract][Full Text] [Related]
9. Sequences within domain II of the urokinase receptor critical for differential ligand recognition.
Li Y; Lawrence DA; Zhang L
J Biol Chem; 2003 Aug; 278(32):29925-32. PubMed ID: 12761227
[TBL] [Abstract][Full Text] [Related]
10. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes.
Chavakis T; Kanse SM; Yutzy B; Lijnen HR; Preissner KT
Blood; 1998 Apr; 91(7):2305-12. PubMed ID: 9516128
[TBL] [Abstract][Full Text] [Related]
11. Regulation of cell adhesion by PAI-1.
Loskutoff DJ; Curriden SA; Hu G; Deng G
APMIS; 1999 Jan; 107(1):54-61. PubMed ID: 10190280
[TBL] [Abstract][Full Text] [Related]
12. The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction.
Høyer-Hansen G; Behrendt N; Ploug M; Danø K; Preissner KT
FEBS Lett; 1997 Dec; 420(1):79-85. PubMed ID: 9450554
[TBL] [Abstract][Full Text] [Related]
13. Reciprocal regulation of urokinase receptor (CD87)-mediated cell adhesion by plasminogen activator inhibitor-1 and protease nexin-1.
Kanse SM; Chavakis T; Al-Fakhri N; Hersemeyer K; Monard D; Preissner KT
J Cell Sci; 2004 Jan; 117(Pt 3):477-85. PubMed ID: 14679304
[TBL] [Abstract][Full Text] [Related]
14. The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor.
Seiffert D; Ciambrone G; Wagner NV; Binder BR; Loskutoff DJ
J Biol Chem; 1994 Jan; 269(4):2659-66. PubMed ID: 7507927
[TBL] [Abstract][Full Text] [Related]
15. Evidence for a specific interaction of vitronectin with arginine: effects of reducing agents on the expression of functional domains and immunoepitopes.
Seiffert D; Wagner NV
Biochimie; 1997 Apr; 79(4):205-10. PubMed ID: 9242985
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms of zinc-dependent leukocyte adhesion involving the urokinase receptor and beta2-integrins.
Chavakis T; May AE; Preissner KT; Kanse SM
Blood; 1999 May; 93(9):2976-83. PubMed ID: 10216093
[TBL] [Abstract][Full Text] [Related]
17. Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system.
Stahl A; Mueller BM
Int J Cancer; 1997 Mar; 71(1):116-22. PubMed ID: 9096674
[TBL] [Abstract][Full Text] [Related]
18. Variability in the expression of urokinase receptor (CD87) mutants on cells: relevance to cell adhesion.
Kanse SM; Chavakis T; Kuo A; Bdeir K; Cines DB; Preissner KT
Cell Biochem Funct; 2004; 22(4):257-64. PubMed ID: 15248186
[TBL] [Abstract][Full Text] [Related]
19. Disulfide bonding arrangements in active forms of the somatomedin B domain of human vitronectin.
Kamikubo Y; De Guzman R; Kroon G; Curriden S; Neels JG; Churchill MJ; Dawson P; Ołdziej S; Jagielska A; Scheraga HA; Loskutoff DJ; Dyson HJ
Biochemistry; 2004 Jun; 43(21):6519-34. PubMed ID: 15157085
[TBL] [Abstract][Full Text] [Related]
20. The reduced, denatured somatomedin B domain of vitronectin refolds into a stable, biologically active molecule.
Kamikubo Y; Kroon G; Curriden SA; Dyson HJ; Loskutoff DJ
Biochemistry; 2006 Mar; 45(10):3297-306. PubMed ID: 16519524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
